A carregar...
Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil
BACKGROUND: Chronic hepatitis C affects approximately 170 million people worldwide, and thus being one of the main causes of chronic liver disease. About 20% of patients with chronic hepatitis C will develop cirrhosis over 20 years, and present an increased risk of developing hepatic complications....
Na minha lista:
| Main Authors: | , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3851805/ https://ncbi.nlm.nih.gov/pubmed/24103591 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1478-7547-11-25 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|